Quest Magazine

UPDATE: Pfizer and Repligen to Collaborate on SMA Therapy Development

The biotechnology firm Repligen today announced it has entered into an agreement with the global pharmaceutical company Pfizer to advance Repligen’s spinal muscular atrophy (SMA) program, which includes RG3039, an experimental drug for SMA whose development MDA has supported.

DMD: Summit Granted Patents for Utrophin Booster

Summit PLC, a biotechnology company based in Abingdon, United Kingdom, has announced it now has two U.S. patents for its experimental drug SMT C1100 for Duchenne muscular dystrophy (DMD).

The patents will provide commercial protection to the company as it continues the further development of this drug. However, the drug will not become available to patients until it receives approval from regulatory agencies.

48th Annual MDA Telethon Raises $59.6 Million To Fight Back Against Muscle Disease

MDA Telethon at $54.1 Million, Giving Invited Through Midnight Monday

Reflections from MDA’s New CEO on the Eve of the Show of Strength Telethon

August 31, 2013

The MDA telethon is an American tradition.

Grand Ole Opry Performance by Luke Bryan To Be Shown on MDA Show of Strength Telethon

DMD: Prosensa Announces New Grant and Provides Exon-Skipping Update

Dutch biotechnology company Prosensa, developer of experimental drugs to treat Duchenne muscular dystrophy (DMD) using exon skipping, announced encouraging developments in an Aug. 28, 2013, press release.

Austin Mahone To Perform on MDA Show of Strength Telethon

SMA: Full Speed Ahead

A Closer Look: SMA Slideshow

Paula Abdul To Give Special Presentation on MDA Telethon Labor Day Weekend

Pages